![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig1_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![No7 Laboratories Line Correcting Booster Serum, Targeted, Results-Driven Formula, Suitable for Sensitive Skin, 0.84 Ounce - Walmart.com No7 Laboratories Line Correcting Booster Serum, Targeted, Results-Driven Formula, Suitable for Sensitive Skin, 0.84 Ounce - Walmart.com](https://i5.walmartimages.com/asr/f51fef07-56ab-4ce3-a2d3-5de45a9c2ea3.8a9b020401dc25a936f5109752f041f6.jpeg)
No7 Laboratories Line Correcting Booster Serum, Targeted, Results-Driven Formula, Suitable for Sensitive Skin, 0.84 Ounce - Walmart.com
![Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/622be947-86d5-4fbd-acdb-e5e4c1a45709/gr1.jpg)
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases
![Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine | Nature Communications Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-29578-w/MediaObjects/41467_2022_29578_Fig1_HTML.png)
Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine | Nature Communications
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig2_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales - The Lancet Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales - The Lancet](https://www.thelancet.com/cms/asset/43c19cc3-58f4-41c4-8c50-86f1f443c0fb/gr1.jpg)
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales - The Lancet
![COVID-19 Update: Bivalent Pfizer and Moderna COVID-19 Vaccines for Booster Immunization | The Medical Letter Inc. COVID-19 Update: Bivalent Pfizer and Moderna COVID-19 Vaccines for Booster Immunization | The Medical Letter Inc.](https://secure.medicalletter.org/images/TML1660c-1.png)
COVID-19 Update: Bivalent Pfizer and Moderna COVID-19 Vaccines for Booster Immunization | The Medical Letter Inc.
![Houston Methodist's Mandate of Covid-19 Vaccine Boosters Among Health Care Workers: Setting Precedents During Unprecedented Times | Catalyst non-issue content Houston Methodist's Mandate of Covid-19 Vaccine Boosters Among Health Care Workers: Setting Precedents During Unprecedented Times | Catalyst non-issue content](https://catalyst.nejm.org/cms/asset/ef2574aa-bcec-4249-8224-c411c913fa98/cat.22.0017-f1.jpg)
Houston Methodist's Mandate of Covid-19 Vaccine Boosters Among Health Care Workers: Setting Precedents During Unprecedented Times | Catalyst non-issue content
![Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://www.thelancet.com/cms/attachment/966d70c5-8395-4ea2-9a35-94dc18f2f550/gr1.gif)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
![Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health](https://www.thelancet.com/cms/asset/317ba83b-0864-4f92-bfd5-473f45a92e43/gr1.gif)
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
![Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review - Chenchula - 2022 - Journal of Medical Virology - Wiley Online Library Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review - Chenchula - 2022 - Journal of Medical Virology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/51e921fa-c870-4d07-b200-339c6083b947/jmv27697-fig-0001-m.png)
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review - Chenchula - 2022 - Journal of Medical Virology - Wiley Online Library
![FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN FDA vaccine advisers 'disappointed' and 'angry' that early data about new Covid-19 booster shot wasn't presented for review last year | CNN](https://media.cnn.com/api/v1/images/stellar/prod/230109124641-moderna-bivalent-vaccine.jpg?c=16x9)